Skip to main content
Erschienen in: Journal of Clinical Immunology 7/2015

01.10.2015 | Astute Clinician Report

Cerebral Vasculitis in X-linked Lymphoproliferative Disease Cured by Matched Unrelated Cord Blood Transplant

verfasst von: Paul E. Gray, Tracey A. O’Brien, Mayura Wagle, Stuart G. Tangye, Umaimainthan Palendira, Tony Roscioli, Sharon Choo, Rosemary Sutton, John B. Ziegler, Katie Frith

Erschienen in: Journal of Clinical Immunology | Ausgabe 7/2015

Einloggen, um Zugang zu erhalten

Abstract

Vasculitis occurs rarely in association with X-linked lymphoproliferative disease (XLP). There are four published cases of non-EBV XLP-associated cerebral vasculitis reported, none of whom have survived without major cognitive impairment.

Case

A 9-year old boy initially presented aged 5 years with a restrictive joint disease. He subsequently developed dysgammaglobulinemia, episodic severe pneumonitis, aplastic anaemia, gastritis and cerebral vasculitis. A diagnosis of XLP was made, based on flow cytometric analysis and the identification of a novel mutation in SH2D1A, c.96G>C. No peripheral blood lymphocyte clonal proliferation was identified and he was EBV negative, although human herpes virus-7 (HHV7) was detected repeatedly in his cerebrospinal fluid. He underwent a reduced intensity unrelated umbilical cord blood transplant, but failed to engraft. A second 5/6 matched cord gave 100 % donor engraftment. Complications included BK virus-associated haemorrhagic cystitis, a possible NK-cell mediated immune reconstitution syndrome and post-transplant anti-glomerular basement membrane disease, the latter treated with cyclophosphamide and rituximab. At +450 days post-transplant he is in remission from his vasculitis and anti-glomerular basement membrane disease, and HHV-7 has remained undetectable.

Conclusion

This is the second published description of joint disease in XLP, and only the fourth case of non-EBV associated cerebral vasculitis in XLP, as well as being the first to be successfully treated for this manifestation. This case raises specific questions about vasculitis in XLP, in particular the potential relevance of HHV-7 to the pathogenesis.
Literatur
1.
Zurück zum Zitat Purtilo DT, Cassel CK, Yang JP, Harper R. X-linked recessive progressive combined variable immunodeficiency (Duncan’s disease). Lancet. 1975;1(7913):935–40.CrossRefPubMed Purtilo DT, Cassel CK, Yang JP, Harper R. X-linked recessive progressive combined variable immunodeficiency (Duncan’s disease). Lancet. 1975;1(7913):935–40.CrossRefPubMed
2.
Zurück zum Zitat Gholam C, Grigoriadou S, Gilmour KC, Gaspar HB. Familial haemophagocytic lymphohistiocytosis: advances in the genetic basis, diagnosis and management. Clin Exp Immunol. 2011;163(3):271–83.PubMedCentralCrossRefPubMed Gholam C, Grigoriadou S, Gilmour KC, Gaspar HB. Familial haemophagocytic lymphohistiocytosis: advances in the genetic basis, diagnosis and management. Clin Exp Immunol. 2011;163(3):271–83.PubMedCentralCrossRefPubMed
3.
Zurück zum Zitat Pachlopnik Schmid J, Canioni D, Moshous D, Touzot F, Mahlaoui N, Hauck F, et al. Clinical similarities and differences of patients with X-linked lymphoproliferative syndrome type 1 (XLP-1/SAP deficiency) versus type 2 (XLP-2/XIAP deficiency). Blood. 2011;117(5):1522–9.CrossRefPubMed Pachlopnik Schmid J, Canioni D, Moshous D, Touzot F, Mahlaoui N, Hauck F, et al. Clinical similarities and differences of patients with X-linked lymphoproliferative syndrome type 1 (XLP-1/SAP deficiency) versus type 2 (XLP-2/XIAP deficiency). Blood. 2011;117(5):1522–9.CrossRefPubMed
4.
Zurück zum Zitat Tangye SG. XLP: clinical features and molecular etiology due to mutations in SH2D1A encoding SAP. J Clin Immunol. 2014;34(7):772–9.CrossRefPubMed Tangye SG. XLP: clinical features and molecular etiology due to mutations in SH2D1A encoding SAP. J Clin Immunol. 2014;34(7):772–9.CrossRefPubMed
5.
Zurück zum Zitat Seemayer TA, Gross TG, Egeler RM, Pirruccello SJ, Davis JR, Kelly CM, et al. X-linked lymphoproliferative disease: twenty-five years after the discovery. Pediatr Res. 1995;38(4):471–8.CrossRefPubMed Seemayer TA, Gross TG, Egeler RM, Pirruccello SJ, Davis JR, Kelly CM, et al. X-linked lymphoproliferative disease: twenty-five years after the discovery. Pediatr Res. 1995;38(4):471–8.CrossRefPubMed
6.
Zurück zum Zitat Booth C, Gilmour KC, Veys P, Gennery AR, Slatter MA, Chapel H, et al. X-linked lymphoproliferative disease due to SAP/SH2D1A deficiency: a multicenter study on the manifestations, management and outcome of the disease. Blood. 2011;117(1):53–62.PubMedCentralCrossRefPubMed Booth C, Gilmour KC, Veys P, Gennery AR, Slatter MA, Chapel H, et al. X-linked lymphoproliferative disease due to SAP/SH2D1A deficiency: a multicenter study on the manifestations, management and outcome of the disease. Blood. 2011;117(1):53–62.PubMedCentralCrossRefPubMed
7.
Zurück zum Zitat Kanegane H, Ito Y, Ohshima K, Shichijo T, Tomimasu K, Nomura K, et al. X-linked lymphoproliferative syndrome presenting with systemic lymphocytic vasculitis. Am J Hematol. 2005;78(2):130–3.CrossRefPubMed Kanegane H, Ito Y, Ohshima K, Shichijo T, Tomimasu K, Nomura K, et al. X-linked lymphoproliferative syndrome presenting with systemic lymphocytic vasculitis. Am J Hematol. 2005;78(2):130–3.CrossRefPubMed
8.
Zurück zum Zitat Talaat KR, Rothman JA, Cohen JI, Santi M, Choi JK, Guzman M, et al. Lymphocytic vasculitis involving the central nervous system occurs in patients with X-linked lymphoproliferative disease in the absence of Epstein-Barr virus infection. Pediatr Blood Cancer. 2009;53(6):1120–3.PubMedCentralCrossRefPubMed Talaat KR, Rothman JA, Cohen JI, Santi M, Choi JK, Guzman M, et al. Lymphocytic vasculitis involving the central nervous system occurs in patients with X-linked lymphoproliferative disease in the absence of Epstein-Barr virus infection. Pediatr Blood Cancer. 2009;53(6):1120–3.PubMedCentralCrossRefPubMed
9.
Zurück zum Zitat Zhu J, Zhang Y, Zhen ZJ, Chen Y, Wang J, Cai RQ, et al. Lymphoma and cerebral vasculitis in association with X-linked lymphoproliferative disease. Chin J Cancer. 2013;32(12):673–7.PubMedCentralCrossRefPubMed Zhu J, Zhang Y, Zhen ZJ, Chen Y, Wang J, Cai RQ, et al. Lymphoma and cerebral vasculitis in association with X-linked lymphoproliferative disease. Chin J Cancer. 2013;32(12):673–7.PubMedCentralCrossRefPubMed
10.
Zurück zum Zitat Palendira U, Low C, Chan A, Hislop AD, Ho E, Phan TG, et al. Molecular pathogenesis of EBV susceptibility in XLP as revealed by analysis of female carriers with heterozygous expression of SAP. PLoS Biol. 2011;9(11):e1001187. Palendira U, Low C, Chan A, Hislop AD, Ho E, Phan TG, et al. Molecular pathogenesis of EBV susceptibility in XLP as revealed by analysis of female carriers with heterozygous expression of SAP. PLoS Biol. 2011;9(11):e1001187.
11.
Zurück zum Zitat Morra M, Simarro-Grande M, Martin M, Chen AS, Lanyi A, Silander O, et al. Characterization of SH2D1A missense mutations identified in X-linked lymphoproliferative disease patients. J Biol Chem. 2001;276(39):36809–16.CrossRefPubMed Morra M, Simarro-Grande M, Martin M, Chen AS, Lanyi A, Silander O, et al. Characterization of SH2D1A missense mutations identified in X-linked lymphoproliferative disease patients. J Biol Chem. 2001;276(39):36809–16.CrossRefPubMed
12.
Zurück zum Zitat Yin L, Ferrand V, Lavoue MF, Hayoz D, Philippe N, Souillet G, et al. SH2D1A mutation analysis for diagnosis of XLP in typical and atypical patients. Hum Genet. 1999;105(5):501–5. Yin L, Ferrand V, Lavoue MF, Hayoz D, Philippe N, Souillet G, et al. SH2D1A mutation analysis for diagnosis of XLP in typical and atypical patients. Hum Genet. 1999;105(5):501–5.
13.
Zurück zum Zitat van Dongen JJ, Langerak AW, Bruggemann M, Evans PA, Hummel M, Lavender FL, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 concerted action BMH4-CT98-3936. Leukemia. 2003;17(12):2257–317.CrossRefPubMed van Dongen JJ, Langerak AW, Bruggemann M, Evans PA, Hummel M, Lavender FL, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 concerted action BMH4-CT98-3936. Leukemia. 2003;17(12):2257–317.CrossRefPubMed
14.
Zurück zum Zitat Purtilo DT, Grierson HL, Davis JR, Okano M. The X-linked lymphoproliferative disease: from autopsy toward cloning the gene 1975–1990. Pediatr Pathol. 1991;11(5):685–710.CrossRefPubMed Purtilo DT, Grierson HL, Davis JR, Okano M. The X-linked lymphoproliferative disease: from autopsy toward cloning the gene 1975–1990. Pediatr Pathol. 1991;11(5):685–710.CrossRefPubMed
15.
Zurück zum Zitat Toth B, Soltesz B, Gyimesi E, Csorba G, Veres A, Lanyi A, et al. Severe XLP phenotype caused by a novel intronic mutation in the SH2D1A gene. J Clin Immunol. 2015;35(1):26–31.CrossRef Toth B, Soltesz B, Gyimesi E, Csorba G, Veres A, Lanyi A, et al. Severe XLP phenotype caused by a novel intronic mutation in the SH2D1A gene. J Clin Immunol. 2015;35(1):26–31.CrossRef
16.
Zurück zum Zitat Liu HX, Tong CR, Wang H, Zhu J, Wang F, Cai P, et al. An analysis of etiological and genetic factors of a patient with familial hemophagocytic lymphohistiocytosis. Zhonghua Nei Ke Za Zhi. 2011;50(2):132–5.PubMed Liu HX, Tong CR, Wang H, Zhu J, Wang F, Cai P, et al. An analysis of etiological and genetic factors of a patient with familial hemophagocytic lymphohistiocytosis. Zhonghua Nei Ke Za Zhi. 2011;50(2):132–5.PubMed
17.
Zurück zum Zitat Vrsalovic MM, Korac P, Dominis M, Ostojic S, Mannhalter C, Kusec R. T- and B-cell clonality and frequency of human herpes viruses-6, −8 and Epstein Barr virus in angioimmunoblastic T-cell lymphoma. Hematol Oncol. 2004;22(4):169–77.CrossRefPubMed Vrsalovic MM, Korac P, Dominis M, Ostojic S, Mannhalter C, Kusec R. T- and B-cell clonality and frequency of human herpes viruses-6, −8 and Epstein Barr virus in angioimmunoblastic T-cell lymphoma. Hematol Oncol. 2004;22(4):169–77.CrossRefPubMed
18.
Zurück zum Zitat Sirianni MC, Campagna M, Scaramuzzi D, Carbonari M, Toschi E, Bacigalupo I, et al. Control of human herpes virus type 8-associated diseases by NK cells. Ann N Y Acad Sci. 2007;1096:37–43.CrossRefPubMed Sirianni MC, Campagna M, Scaramuzzi D, Carbonari M, Toschi E, Bacigalupo I, et al. Control of human herpes virus type 8-associated diseases by NK cells. Ann N Y Acad Sci. 2007;1096:37–43.CrossRefPubMed
Metadaten
Titel
Cerebral Vasculitis in X-linked Lymphoproliferative Disease Cured by Matched Unrelated Cord Blood Transplant
verfasst von
Paul E. Gray
Tracey A. O’Brien
Mayura Wagle
Stuart G. Tangye
Umaimainthan Palendira
Tony Roscioli
Sharon Choo
Rosemary Sutton
John B. Ziegler
Katie Frith
Publikationsdatum
01.10.2015
Verlag
Springer US
Erschienen in
Journal of Clinical Immunology / Ausgabe 7/2015
Print ISSN: 0271-9142
Elektronische ISSN: 1573-2592
DOI
https://doi.org/10.1007/s10875-015-0194-9

Weitere Artikel der Ausgabe 7/2015

Journal of Clinical Immunology 7/2015 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.